Pirarubicin Hydrochloride for Injection

This product is a semi-synthetic anthracycline anticancer drug. It enters the cell nucleus and quickly embeds into the DNA base pairs, interfering with the transcription process, preventing mRNA synthesis, inhibiting DNA polymerase and DNA topoisomerase Ⅱ (Topoisomerase Ⅱ, Topo Ⅱ) activity, and interfering with DNA synthesis. Because this product interferes with DNA and mRNA synthesis at the same time, it blocks cells from entering the G1 phase in the cell proliferation cycle, interferes with tumor cell division, and inhibits tumor growth, so it has strong anticancer activity.

The chemical name of this product is: (8S,10S)-[[3-amino-2,3,6-trideoxy-4-O-(2-tetrahydropyranyl)-a-L-arabinopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-hydroxyacetyl-1-methoxy-5,12-naphthalenedione hydrochloride.

This product is orange-red freeze-dried loose blocks or powder.

It has good curative effect on malignant lymphoma and acute leukemia, and is effective for breast cancer, head and neck cancer, gastric cancer, urinary system malignant tumors, ovarian cancer, endometrial cancer, cervical cancer, etc. The effective rate of THP alone is 20% to 70%. The anti-cancer effect is increased when combined with various chemotherapy drugs such as Ara-C, CTX, 6-MP, MTX, 5-FU, DDP, etc.

Add this product to 10ml of 5% glucose injection or water for injection and dissolve. It can be injected intravenously, intraarterially, or intravesically. Intravenous injection: generally 25-40mg/m2 per body surface area; arterial administration: such as head and neck cancer, 7-20mg/m2 per body surface area, once a day, for 5-7 days, or 14-25mg/m2 each time, once a week; intravesical administration: 15-30mg/m2 per body surface area, diluted to a concentration of 500-1000 μg/ml, injected into the bladder cavity and retained for 1-2 hours, 3 times a week as a course of treatment, 2-3 courses of treatment can be used.

1. Bone marrow suppression is a dose-limiting toxicity, mainly granulocytopenia, with an average minimum value of 14 days, recovery on the 21st day, and anemia and thrombocytopenia are rare; 2. Cardiac toxicity is lower than ADM, acute cardiotoxicity is mainly reversible ECG changes, such as arrhythmia or nonspecific ST-T abnormalities, and chronic cardiotoxicity is dose-accumulative; 3. Gastrointestinal reactions: nausea, vomiting, loss of appetite, oral mucositis, and sometimes diarrhea; 4. Others: abnormal liver and kidney function, hair loss, skin pigmentation, etc., and occasionally rash. Intravesical injection may cause bladder irritation symptoms such as frequent urination, painful urination, hematuria, and even bladder atrophy.

It is contraindicated for patients with severe organic heart disease or abnormal heart function and those who are allergic to this product; it is contraindicated for women during pregnancy, lactation and childbearing age.

Precautions for children: When children use this product, they should pay attention to the occurrence of adverse reactions and use this product with caution. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: Elderly patients should use it with caution or reduce the dosage as appropriate.

When this product is used in combination with other potentially cardiotoxic or cytotoxic drugs, cardiotoxicity or bone marrow suppression may be superimposed, and close attention should be paid to monitoring cardiac function and hematology.

Keep away from light and store in sealed container.

10 mg (calculated as C32H37N012)

24 months

ShenZhen Main Luck Pharmaceuticals Inc

• Founded in:

  1990-07-04

• Address:

  Wanle Pharmaceutical Building, National Biomedicine Industry Base, Lanzhu East Road, Pingshan New District, Shenzhen

• Tax NO.:

  91440300618861849X

• Registered Funds:

  $19,544,550

• Website:

  Log in to view

• Email:

  Log in to view